In Solana Beach, California, on September 3, 2025, Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company specializing in modulating lipid-signaling pathways for cancer, pain, dermatologic, and neurological conditions, has initiated an underwritten public offering of its common stock and/or pre-funded warrants. The Company will offer all shares in the offering, and its completion depends on market conditions. This offering does not have a guaranteed timeline for completion or specific details regarding size or terms.